Analysts say head-to-head study results could make Kyprolis the lead treatment.
Drugmakers face increasing pressure on pricing from insurers and PBMs.
The breakthrough designation therapy drug was the first for its drug class.
Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.
Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.
Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.
The organization plans to publish a scientific and a lay abstract detailing study findings
Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.
Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.
The EU will have access to the new medication in May.
Sanofi's Lantus predecessor nabs approval; Pharmacyclics reportedly vets acquisition offers; FDA biosimilar hearing is postponed.
Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.
The over-the-counter weight-loss drug Alli saw a return to drugstores this week after a year hiatus.
J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.
The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.
Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.
Assemblyman David Chiu's bill would publish a drug's R&D and related costs.
FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.
A MedPanel survey indicates doctors have not changed their business practices since the Open Payments database went live.
23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.
Americans may be taking anti-cholesterol medications, but it doesn't mean they are aware of their impact.
The Healthcare Businesswomen's Association named Denice Torres, president of J&J's McNeil Consumer Healthcare, as its 26th Woman of the Year.
Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.
Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.
A small physician survey shows doctors think their patients have higher adherence rates than the norm.
CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.
A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.
Bayer exec may be Sanofi's new CEO, GSK gets a new North American Pharma lead, and Pfizer sends painkiller ALO-02 to the FDA.
Pfizer's academic research arm will work together with the Alzheimer's Drug Discovery Foundation to jointly invest in scientific research to identify clinical candidates for testing.
The Paris-based drugmaker has axed 100 oncology and global R&D employees as part of a reorganization effort.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.